Valuation: PFIZER

Market Cap 164B 164B 144B 136B 123B 232B 15,713B 233B 1,630B 630B 8,018B 615B 601B 25,766B P/E 2026 *
18.1x
P/E 2027 * 14x
Enterprise Value 211B 211B 186B 176B 159B 299B 20,271B 301B 2,103B 812B 10,344B 793B 776B 33,240B EV / Sales 2026 *
3.39x
EV / Sales 2027 * 3.42x
Free-Float
59.05%
Yield 2026 *
5.99%
Yield 2027 * 6.04%
Manager TitleAgeSince
Chief Executive Officer 64 01/01/2019
Director of Finance/CFO 55 16/08/2026
Compliance Officer 65 01/12/2013
Director TitleAgeSince
Director/Board Member 68 01/09/2007
Director/Board Member 62 27/09/2013
Chairman 64 01/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.90%-0.06%+60.97%+117.73% 1,056B
-1.98%-1.30%+46.29%+70.59% 655B
-1.45%-1.14%+17.49%+75.89% 471B
-1.81%-4.15%+36.27%+39.35% 342B
-0.51%+3.66%+21.88%+28.60% 277B
-0.46%-1.86%+12.16%+12.02% 257B
-0.52%+1.36%+51.78%+54.72% 226B
-1.94%-2.23%+32.53%+99.17% 189B
-0.24%-2.82%-28.45%-60.94% 170B
Average -1.08%+0.97%+27.88%+48.57% 404.77B
Weighted average by Cap. -1.20%+1.04%+37.77%+69.05%

Financials

2026 *2027 *
Net sales 62.24B 62.24B 54.74B 51.76B 46.95B 88.17B 5,974B 88.68B 620B 239B 3,048B 234B 229B 9,796B 59.77B 59.77B 52.56B 49.71B 45.08B 84.67B 5,737B 85.16B 595B 230B 2,927B 224B 220B 9,407B
Net income 8.9B 8.9B 7.83B 7.4B 6.71B 12.61B 854B 12.68B 88.63B 34.23B 436B 33.42B 32.69B 1,401B 11.08B 11.08B 9.75B 9.22B 8.36B 15.7B 1,064B 15.79B 110B 42.61B 543B 41.6B 40.7B 1,744B
Net Debt 47.48B 47.48B 41.76B 39.49B 35.82B 67.27B 4,558B 67.66B 473B 183B 2,326B 178B 174B 7,474B 40.98B 40.98B 36.04B 34.08B 30.91B 58.06B 3,934B 58.39B 408B 158B 2,007B 154B 151B 6,450B
Logo PFIZER
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (42.9%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (28%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (26.9%); - other (2.2%). The United States accounts for 59.2% of net sales.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A